Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents

Cancer Genomics - Proteomics

MICHAEL MEDINGER¹  JÖRG HALTER²  DOMINIK HEIM²  ANDREAS BUSER²  JAKOB PASSWEG²  CLAUDIA LENGERKE²  SABINE GERULL² 

[1] ivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland;ivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerlandivision of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland

关键词: Angiogenesis;    bortezomib;    gene expression;    immunomodulatory drugs;    plasma cell myeloma;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Background/Aim: Novel agents such as thalidomide, lenalidomide and bortezomib have in part anti-angiogenic properties. In this study, we examined gene expression of angiogenic molecules in patients with plasma cell myeloma (PCM). Materials and Methods: We included 93 patients with PCM treated with novel agents (immunomodulatory drugs (IMiDs), bortezomib or a combination of both). The mRNA levels of angiogenic molecules were measured using the Human Angiogenesis RT2 Profiler PCR Array. The response evaluation was performed after three cycles. Results: Regarding all 93 patients, gene expression of 15 out of 84 genes tested (pre- and post-treatment and changes in levels pre-treatment/post-treatment) were significantly different in responders compared to non-responders. Responders had a lower expression of pro-angiogenic factors and increased expression of antiangiogenic factors. Conclusion: In the IMiD-treated groups we found significant changes of expression of angiogenic genes in responders compared to non-responders, whereas in the bortezomib-based group the difference in expression of angiogenic genes was not significant.

【 授权许可】

Unknown